Precision oncology and digitally enabled cancer care are transforming what it means to live with cancer. The number of people in Europe alive more than five years after a cancer diagnosis grew 41 percent between 2010 and 2020, to nearly 15 million. As science progresses, a growing number of advanced cancers could be managed as chronic diseases, like diabetes or hypertension.
But many patients are only able to access innovative treatments as part of a clinical trial, and Europe’s share of global commercial trials has almost halved in a decade. Access to screening and advanced diagnostics also varies widely across the bloc.
In the first of two special podcast episodes produced by POLITICO Studio, experts in oncology, clinical research and drug development explore how precision oncology works, how artificial intelligence can draw on vast pools of health data to develop new treatments and where science is heading next.
Guest speakers include: Fatima Cardoso, head of clinical trials, scientific affairs and international development in breast oncology at the Centre Antoine Lacassagne in Nice, France, and president of the Advanced Breast Cancer Global Alliance; Giuseppe Curigliano, professor of medical oncology at the University of Milan and head of the Division of Early Drug Development at the European Institute of Oncology; and Johanna Bendell, chief development officer, oncology for Pfizer.
POLITICAL ADVERTISEMENT
- The sponsor is Pfizer Inc., 66 Hudson Blvd E, New York, NY 10001, USA.
- The political advertising is related to calls for EU policymakers to improve access to precision cancer care.
More information here.